NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, News, & Analysis

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its earnings results on Wednesday, February, 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.17) by $0.15. The biotechnology company earned $130.70 million during the quarter, compared to analyst estimates of $96.57 million. The business's quarterly revenue was up 38.7% compared to the same quarter last year. During the same period last year, the business earned ($0.14) EPS. View Ironwood Pharmaceuticals' Earnings History.

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals issued an update on its FY 2019 earnings guidance on Wednesday, February, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $370-390 million, compared to the consensus revenue estimate of $377.33 million.

13 equities research analysts have issued 12 month price targets for Ironwood Pharmaceuticals' stock. Their predictions range from $11.00 to $25.00. On average, they anticipate Ironwood Pharmaceuticals' stock price to reach $17.35 in the next twelve months. This suggests a possible upside of 29.5% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 1 sell rating, 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals.

Media coverage about IRWD stock has trended neutral this week, according to InfoTrie. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ironwood Pharmaceuticals earned a coverage optimism score of 0.4 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days.

Some companies that are related to Ironwood Pharmaceuticals include Bausch Health Companies (BHC), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), Marina Biotech (MRNA), Loxo Oncology (LOXO), Amarin (AMRN), Perrigo (PRGO), Nektar Therapeutics (NKTR), Catalent (CTLT), Ascendis Pharma A/S (ASND), Alkermes (ALKS), Array Biopharma (ARRY), GW Pharmaceuticals PLC- (GWPH), GALAPAGOS NV/S (GLPG) and FibroGen (FGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Micron Technology (MU), Chipotle Mexican Grill (CMG), YY (YY), Allergan (AGN), NIC (EGOV), Celldex Therapeutics (CLDX) and Athabasca Oil (ATH).

Ironwood Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include MFN Partners Management LP (3.21%), Orbimed Advisors LLC (1.87%), Westfield Capital Management Co. LP (1.28%), Norges Bank (1.23%), Northern Trust Corp (1.11%) and Geode Capital Management LLC (1.08%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

IRWD stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, New York State Common Retirement Fund, PNC Financial Services Group Inc., First Trust Advisors LP, MetLife Investment Advisors LLC, California Public Employees Retirement System, Bank of New York Mellon Corp and Fisher Asset Management LLC. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.

IRWD stock was acquired by a variety of institutional investors in the last quarter, including MFN Partners Management LP, Norges Bank, Millennium Management LLC, D. E. Shaw & Co. Inc., Canada Pension Plan Investment Board, Caption Management LLC, Ontario Teachers Pension Plan Board and Westfield Capital Management Co. LP. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IRWD stock can currently be purchased for approximately $13.40.

Ironwood Pharmaceuticals has a market capitalization of $2.07 billion and generates $346.64 million in revenue each year. The biotechnology company earns $-282,370,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

The official website for Ironwood Pharmaceuticals is http://www.ironwoodpharma.com.

Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]